Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA

H. E. Hsu, Chara Rydzak, K. L. Cotich, B. Wang, P. E. Sax, E. Losina, K. A. Freedberg, S. J. Goldie, Z. Lu, R. P. Walensky

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA. Methods We used data from the Women's Interagency HIV Study in an HIV disease simulation model to estimate life expectancy in women who receive an efavirenz-based initial antiretroviral regimen compared with those who delay efavirenz use and receive a boosted protease inhibitor-based initial regimen. To estimate excess risk of teratogenic events with and without efavirenz exposure per 100000 women, we incorporated literature-based rates of pregnancy, live births, and teratogenic events into a decision analytic model. We assumed a teratogenicity risk of 2.90 events/100 live births in women exposed to efavirenz during pregnancy and 2.68/100 live births in unexposed women. Results Survival for HIV-infected women who received an efavirenz-based initial antiretroviral therapy (ART) regimen was 0.89 years greater than for women receiving non-efavirenz-based initial therapy (28.91 vs. 28.02 years). The rate of teratogenic events was 77.26/100000 exposed women, compared with 72.46/100000 unexposed women. Survival estimates were sensitive to variations in treatment efficacy and AIDS-related mortality. Estimates of excess teratogenic events were most sensitive to pregnancy rates and number of teratogenic events/100 live births in efavirenz-exposed women. Conclusions Use of non-efavirenz-based initial ART in HIV-infected women of childbearing age may reduce life expectancy gains from antiretroviral treatment, but may also prevent teratogenic events. Decision-making regarding efavirenz use presents a trade-off between these two risks; this study can inform discussions between patients and health care providers.

Original languageEnglish (US)
Pages (from-to)97-108
Number of pages12
JournalHIV Medicine
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

efavirenz
HIV
Live Birth
Life Expectancy
Pregnancy Rate

Keywords

  • Efavirenz
  • HIV/AIDS
  • Teratogenicity
  • Women

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. / Hsu, H. E.; Rydzak, Chara; Cotich, K. L.; Wang, B.; Sax, P. E.; Losina, E.; Freedberg, K. A.; Goldie, S. J.; Lu, Z.; Walensky, R. P.

In: HIV Medicine, Vol. 12, No. 2, 01.02.2011, p. 97-108.

Research output: Contribution to journalArticle

Hsu, HE, Rydzak, C, Cotich, KL, Wang, B, Sax, PE, Losina, E, Freedberg, KA, Goldie, SJ, Lu, Z & Walensky, RP 2011, 'Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA', HIV Medicine, vol. 12, no. 2, pp. 97-108. https://doi.org/10.1111/j.1468-1293.2010.00856.x
Hsu, H. E. ; Rydzak, Chara ; Cotich, K. L. ; Wang, B. ; Sax, P. E. ; Losina, E. ; Freedberg, K. A. ; Goldie, S. J. ; Lu, Z. ; Walensky, R. P. / Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. In: HIV Medicine. 2011 ; Vol. 12, No. 2. pp. 97-108.
@article{380137cc570b48f5860bb17965f35081,
title = "Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA",
abstract = "Objectives The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA. Methods We used data from the Women's Interagency HIV Study in an HIV disease simulation model to estimate life expectancy in women who receive an efavirenz-based initial antiretroviral regimen compared with those who delay efavirenz use and receive a boosted protease inhibitor-based initial regimen. To estimate excess risk of teratogenic events with and without efavirenz exposure per 100000 women, we incorporated literature-based rates of pregnancy, live births, and teratogenic events into a decision analytic model. We assumed a teratogenicity risk of 2.90 events/100 live births in women exposed to efavirenz during pregnancy and 2.68/100 live births in unexposed women. Results Survival for HIV-infected women who received an efavirenz-based initial antiretroviral therapy (ART) regimen was 0.89 years greater than for women receiving non-efavirenz-based initial therapy (28.91 vs. 28.02 years). The rate of teratogenic events was 77.26/100000 exposed women, compared with 72.46/100000 unexposed women. Survival estimates were sensitive to variations in treatment efficacy and AIDS-related mortality. Estimates of excess teratogenic events were most sensitive to pregnancy rates and number of teratogenic events/100 live births in efavirenz-exposed women. Conclusions Use of non-efavirenz-based initial ART in HIV-infected women of childbearing age may reduce life expectancy gains from antiretroviral treatment, but may also prevent teratogenic events. Decision-making regarding efavirenz use presents a trade-off between these two risks; this study can inform discussions between patients and health care providers.",
keywords = "Efavirenz, HIV/AIDS, Teratogenicity, Women",
author = "Hsu, {H. E.} and Chara Rydzak and Cotich, {K. L.} and B. Wang and Sax, {P. E.} and E. Losina and Freedberg, {K. A.} and Goldie, {S. J.} and Z. Lu and Walensky, {R. P.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1111/j.1468-1293.2010.00856.x",
language = "English (US)",
volume = "12",
pages = "97--108",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA

AU - Hsu, H. E.

AU - Rydzak, Chara

AU - Cotich, K. L.

AU - Wang, B.

AU - Sax, P. E.

AU - Losina, E.

AU - Freedberg, K. A.

AU - Goldie, S. J.

AU - Lu, Z.

AU - Walensky, R. P.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Objectives The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA. Methods We used data from the Women's Interagency HIV Study in an HIV disease simulation model to estimate life expectancy in women who receive an efavirenz-based initial antiretroviral regimen compared with those who delay efavirenz use and receive a boosted protease inhibitor-based initial regimen. To estimate excess risk of teratogenic events with and without efavirenz exposure per 100000 women, we incorporated literature-based rates of pregnancy, live births, and teratogenic events into a decision analytic model. We assumed a teratogenicity risk of 2.90 events/100 live births in women exposed to efavirenz during pregnancy and 2.68/100 live births in unexposed women. Results Survival for HIV-infected women who received an efavirenz-based initial antiretroviral therapy (ART) regimen was 0.89 years greater than for women receiving non-efavirenz-based initial therapy (28.91 vs. 28.02 years). The rate of teratogenic events was 77.26/100000 exposed women, compared with 72.46/100000 unexposed women. Survival estimates were sensitive to variations in treatment efficacy and AIDS-related mortality. Estimates of excess teratogenic events were most sensitive to pregnancy rates and number of teratogenic events/100 live births in efavirenz-exposed women. Conclusions Use of non-efavirenz-based initial ART in HIV-infected women of childbearing age may reduce life expectancy gains from antiretroviral treatment, but may also prevent teratogenic events. Decision-making regarding efavirenz use presents a trade-off between these two risks; this study can inform discussions between patients and health care providers.

AB - Objectives The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA. Methods We used data from the Women's Interagency HIV Study in an HIV disease simulation model to estimate life expectancy in women who receive an efavirenz-based initial antiretroviral regimen compared with those who delay efavirenz use and receive a boosted protease inhibitor-based initial regimen. To estimate excess risk of teratogenic events with and without efavirenz exposure per 100000 women, we incorporated literature-based rates of pregnancy, live births, and teratogenic events into a decision analytic model. We assumed a teratogenicity risk of 2.90 events/100 live births in women exposed to efavirenz during pregnancy and 2.68/100 live births in unexposed women. Results Survival for HIV-infected women who received an efavirenz-based initial antiretroviral therapy (ART) regimen was 0.89 years greater than for women receiving non-efavirenz-based initial therapy (28.91 vs. 28.02 years). The rate of teratogenic events was 77.26/100000 exposed women, compared with 72.46/100000 unexposed women. Survival estimates were sensitive to variations in treatment efficacy and AIDS-related mortality. Estimates of excess teratogenic events were most sensitive to pregnancy rates and number of teratogenic events/100 live births in efavirenz-exposed women. Conclusions Use of non-efavirenz-based initial ART in HIV-infected women of childbearing age may reduce life expectancy gains from antiretroviral treatment, but may also prevent teratogenic events. Decision-making regarding efavirenz use presents a trade-off between these two risks; this study can inform discussions between patients and health care providers.

KW - Efavirenz

KW - HIV/AIDS

KW - Teratogenicity

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=79954577281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954577281&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2010.00856.x

DO - 10.1111/j.1468-1293.2010.00856.x

M3 - Article

VL - 12

SP - 97

EP - 108

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 2

ER -